{"groups":[{"description":"Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity.\n\nsaracatinib: Given orally","id":"FG000","title":"Arm I AZD0530"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}